Revenue up 15.5%, but Crop Protection margin halved
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Guided 15-17% EBITDA margin for Crop Protection; delivered 11%. All other consolidated numbers (revenue ₹666.9, PAT ₹33.9) hit exactly. Long-term targets not yet tested.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Revenue momentum solid at 15.5% YoY, but Crop Protection segment EBITDA margin crushed from 15-17% guidance to 11% due to elevated raw material costs and logistics. QoQ PAT declined 29.7%. Management acknowledges near-term cost pressure, expects normalization, and targets double-digit growth long-term via new Crop Nutrition products. Key risk: TiO2 operations suspended indefinitely; trade receivables spike suggests market stress.
₹666.9 Cr
Revenue · +15.5% YoY₹33.9 Cr
Reported PAT · +193.3% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Consolidated revenue INR666 crores, up 16% YoY
METDelivered ₹666.9 Cr, +15.5% YoY
Consolidated net profit INR33.9 crores, up 193% YoY
METDelivered ₹33.9 Cr PAT, +193.3% YoY
Crop Protection segment 11% EBITDA margin
OVERSTATEDSegment reported ₹54 Cr EBITDA on ₹496 Cr = 10.9%, vs prior guidance 15-17%
Logistics cost rising gradually normalizing
MISSManagement cites 'sharp increase'; normalization timeline unclear; trade receivables jumped to ₹220 Cr
EBITDA grew 40% YoY to INR73 crores
METDelivered implied EBITDA ~₹73-74 Cr; growth rate aligns
Earnings quality
What changed since the last call
Crop Protection margin guidance
DowngradeQ1 FY27 call guided 15-17% EBITDA margin. Q2 delivered 11%. Management did not formally cut guidance but acknowledged 'sharp increase' in input and logistics costs, now managing costs to improve.
Trade receivables management
DowngradeReceivables up ₹220 Cr (magnitude not disclosed vs baseline). Cycle extended from 100-110 to 110-115 days. Management cites customer support in challenging market; implies credit risk or demand softness.
TiO2 sector outlook
WithdrawnOperations 'remain suspended due to commercial unviability' (re-imposed antidumping duty Oct 2026, sulfuric acid 7-8x normal). No restart timeline. Prior contribution to consolidated profit now at risk indefinitely.
Crop Nutrition conviction
UpgradeManagement reaffirmed very optimistic outlook. Nano DAP, Nano NPK, Nano Zinc launched; field trials positive. Now claiming 20-22% EBITDA contribution to company over next 3 years; prior guidance was ₹100 Cr revenue over 2-3 years.
Pigments segment outlook
NeutralMaintained ₹600-650 Cr annualized revenue, 10-11% EBITDA margin. Q2 on track (~₹161 Cr quarterly = ₹644 Cr annualized). No significant change.
The Q&A
Analysts pressed hard on margin miss (Yash Somani on Crop Protection 15-17% vs 11%), trade receivables spike (Ayush J), revenue growth vs margin trade-off (Khushi Solanki on 40% growth but lower profitability). Management held firm on long-term targets, cited temporary cost headwinds, and claimed cost actions underway. No signs of defensive evasion; direct answers on raw material (up 7-8x), logistics (normalizing), and market dynamics (challenging but stabilizing). Generally credible but cautious tone throughout.
Trade receivables spike — Ayush J, Individual Investor
PartialMarkets offered more credit to push sales. Cycle extended to 125+ days from 100-110. Management expects improvement if market demand improves; likely 110-115 days going forward.
Crop Protection margin miss — Yash Somani, Somani Family Office
PartialRaw materials spiked due to war, energy costs up. Holding low-cost inventory helped Q1. Logistics costs rising but expected to normalize in months. Product mix optimization and cost management underway.
Revenue growth quality — Khushi Solanki, Agrawal & Co
AnsweredPartly currency momentum (₹ depreciation), partly product mix (better realization on some SKUs). Cost headwinds offset pricing power. Company focused on sustaining growth and profitability.
Product pipeline — Khushi Solanki, Agrawal & Co
AnsweredProducts registered up to 2031 across 70+ countries. Registrations in Latin America, North Africa, Asia underway. Process is slow; each country different. Expect continuous registrations to drive growth.
Geographic demand — Khushi Solanki, Agrawal & Co
AnsweredEurope challenging; cost up, demand impacted by price pass-through difficulty. US has tariff issue impacting pigments. Agrotech elsewhere (Latin America, Africa) strong. Company not focused on Europe; most business in rest of world.
New chemistry entry — Rushali Sadani, Arihant Capital
DodgedR&D ongoing under wraps. New products in development but kept confidential until commercialization. Once success and viability confirmed, company will launch.
Byproducts revenue — Rushali Sadani, Arihant Capital
AnsweredLess than 1% of revenue. Very small contributor. Not a focus area.
Contingent liabilities — Rushali Sadani, Arihant Capital
AnsweredNo major contingent liabilities. (Confirmed by CFO G.S. Chahal.)
Pigment realization trend — Rushali Sadani, Arihant Capital
PartialMarket accepted price increases along with raw material increases. Company passed through raw material cost. Realized better profitability in Q1-Q2. EBITDA measurement (not per-kg) preferred due to product mix variation.
Crop Nutrition outlook — Shayan, Make Money Organic
AnsweredNano urea facing adoption issues due to marketing; Nano DAP more positive. Company positioned well with large customer base. Nano DAP adoption increasing in field trials. Expect good growth over 3 years; will contribute 20-22% EBITDA to company.
Capacity utilization Crop Nutrition — Shayan, Make Money Organic
AnsweredYes, as product demand grows and stabilizes, company can improve utilization going forward.
Dividend outlook — Shayan, Make Money Organic
AnsweredCompany gave regular dividends historically. Last 2-3 years volatile; focused on cash preservation. If cash flow improves and market stabilizes, will announce dividends. Focus now on cash generation.
Guidance
Crop Protection double-digit growth over 2-3 years from top line
HighManagement reaffirmed; product pipeline to 2031 backs claim. New registrations in progress.
Pigments ₹600-650 Cr annualized revenue (no significant growth)
HighQ2 rate of ₹161 Cr/quarter implies ~₹644 Cr annualized. On track.
Crop Nutrition ~₹100 Cr revenue over 2-3 years (₹33 Cr/year average)
MediumEarly stage launch; Nano products in adoption phase. Management upbeat but execution risk high given initial slow uptake of Nano urea.
Crop Protection 15-17% EBITDA margin long-term target
MediumQ2 missed at 11%. Management cites temporary cost spike; claims cost normalization and product mix optimization will drive recovery. Timeframe uncertain.
Pigments 10-11% EBITDA margin
HighQ2 at 10%; management targeting 10-11%. In line.
Consolidated 13-14% EBITDA margin long-term
MediumQ2 at 11%. Long-term target hinges on Crop Nutrition growth and Crop Protection recovery. Vague on timeline.
Risks the call surfaced
Margin compression
HighCrop Protection EBITDA margin halved from 15-17% guidance to 11%. Raw materials up 7-8x (sulfuric acid). Logistics costs elevated. Management expects normalization but timeline vague.
Working capital deterioration
MediumTrade receivables jumped to ₹220 Cr. Management extended payment cycle to 110-115 days from 100-110. Attributed to customer support in 'challenging market.' Signals either credit risk or market weakness.
TiO2 operations suspended
HighTiO2 production suspended indefinitely due to sulfuric acid prices at 7-8x normal and re-imposed 5-year antidumping duty (Oct 2026). Economics 'not commercially viable.' No restart timeline provided. This was a prior profit contributor.
Crop Nutrition execution risk
MediumCrop Nutrition segment (Nano DAP, Nano NPK, Nano Zinc) launched recently. Company very optimistic but facing adoption headwinds (Nano urea poor marketing campaign). ₹100 Cr revenue target over 2-3 years is material but not yet visible. Field trials positive but early-stage risks remain.
Geopolitical and trade headwinds
MediumEurope market challenging (cost inflation, demand weakness). US tariff issue impacted pigment business last year; unsure if recurring this year. Middle East conflict creates raw material supply volatility. Company exposure low on Europe (1% of agrotech), moderate on US (tariff impact).
Management
Score 7/10. Clear on challenges (margin miss, cost spike, TiO2 suspension) and action items (product mix, cost mgmt, new registrations). Transparent about trade receivables extension. However, vague on timing for cost normalization and TiO2 restart. Evasive on new product details (IP protection valid). Mixed. Consolidated numbers (revenue, profit) hit guidance exactly. But Crop Protection margin missed 15-17% target by ~5 pts. Debt repayment on track (₹64 Cr HY). HY growth only 3% YoY (Q1 was weak), so Q2's 15.5% not sustainable near-term. Execution risk on new Crop Nutrition products.
1 · Q3 FY27 (Dec 2026)
Input cost and logistics normalization; margin recovery signal
2 · FY27 (Mar 2027)
Crop Nutrition Nano products scale ramp; contribution to profits visible
3 · CY2027 (anytime)
TiO2 duty policy revision or sulfuric acid price relief; restart consideration
Key risk: TiO2 operations suspended indefinitely; trade receivables spike suggests market stress.
Meghmani Organics: PAT jumps 193% YoY on Pigments turnaround, Agrochem margin cools QoQ
PAT +193.33% YoY · revenue +15.53% · margins expanding
₹666.92 Cr
+15.53% YoY
₹33.88 Cr
+193.33% YoY
4.93%
+3pp YoY
₹1.33
Meghmani Organics' consolidated PAT rose 193.3% YoY to ₹33.88 Cr in Q2 FY27 (quarter ended Sep-26) from ₹11.55 Cr a year ago, as revenue grew 15.5% YoY to ₹666.92 Cr. NPM expanded to 4.93% from 1.91% and OPM to 10.97% from 9.02% YoY. Sequentially, though, PAT fell 29.7% QoQ from ₹48.19 Cr even as revenue rose 22.9% QoQ from ₹542.83 Cr — margins compressed sharply from Q1 FY27's NPM of 8.69%/OPM of 18.04%, which was an unusually strong quarter. Basic EPS was ₹1.33 versus ₹0.45 a year ago and ₹1.90 last quarter. No exceptional items were reported in either period.
Q2 FY-2027 vs prior quarters
The YoY profit jump is almost entirely a Pigments/TiO2 story, not a broad-based improvement. The Pigments segment swung to a ₹7.27 Cr profit from a ₹20.81 Cr loss a year ago (segment revenue up 43.8% YoY to ₹187.28 Cr), consistent with management's guidance on the Q1 FY27 call that TiO2 operations — largely shut through FY27 after an anti-dumping-duty withdrawal — would recover from Q2. Agrochemicals (Crop Protection, ~75% of consolidated revenue), the core segment, told the opposite story: revenue grew 12.2% YoY to ₹496.75 Cr and 26.9% QoQ, but segment profit fell 33.1% YoY to ₹53.14 Cr and 24.1% QoQ from ₹70.06 Cr, as costs outran pricing — standalone cost of materials consumed climbed to 66.6% of revenue from 58.5% last quarter and 61.3% a year ago. Lower finance costs (₹14.97 Cr vs ₹23.78 Cr YoY, down 37%) also helped the PBT line.
The stock went into the print at ₹56.48, up 3% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters.
Crop Protection: double-digit revenue growth over next 2-3 years at 15-17% EBITDA margin. Pigments: ₹550-600 Cr annualized at ~10% EBITDA. Crop Nutrition: ~₹100 Cr revenue over 2-3 years. Annual debt repayment ₹130 Cr.
— This quarter: met
Against management's FY27 targets from the August 2026 call — double-digit Crop Protection growth at 15-17% EBITDA margin, Pigments at ₹550-600 Cr annualised at ~10% EBITDA, and ₹130 Cr annual debt repayment — the quarter is mixed. Crop Protection's double-digit growth held, but its margin trajectory softened sharply from Q1's 19.9% EBITDA level (per a July 2026 Arihant Capital note), landing well below the guided band on an EBIT basis this quarter. Pigments' H1 FY27 run-rate of ~₹662 Cr annualised already tops the guided range, and the swing to segment profit is the first concrete sign of the targeted ~10% EBITDA recovery. H1 FY27 standalone debt fell only ~₹32.7 Cr, roughly half the pace needed to hit the ₹130 Cr annual repayment target. We found no analyst consensus specific to this quarter; the same July note had flagged ~15-20% PAT growth for FY27 overall, and H1 FY27 PAT of ₹82.08 Cr is already up 238.6% YoY — well ahead of that pace, though the comparison period included the TiO2 shutdown. No company press release accompanied this filing. Separately, NCLT Ahmedabad approved the amalgamation of wholly-owned subsidiaries Kilburn Chemicals and Meghmani Crop Nutrition into the parent on October 8, 2026; this has no P&L impact yet as the scheme is not yet effective.
W1
Whether the Pigments/TiO2 segment's ₹7.27 Cr Q2 profit (from a ₹20.81 Cr loss YoY) sustains into Q3 as anti-dumping-duty conditions evolve
W2
Whether Agrochemicals margin claws back toward Q1 FY27's ~19.9% EBITDA level or cost pressure persists (standalone material costs were 66.6% of revenue in Q2 vs 58.5% in Q1)
W3
Progress against the ₹130 Cr annual debt-repayment target — H1 FY27 standalone debt fell only ~₹32.7 Cr, about half the pro-rata pace
No exceptional items in either period/basis; consolidated PBT includes a negligible ₹0.16 Lakh share of loss from associate Pro-Zeal Green Power Fifteen Pvt Ltd; wholly-owned subsidiaries so no minority interest; clean digital PDF with unambiguous column headers, both arithmetic checks tie exactly.
Growth Masking the Real Story: Margins Halved, Receivables Spiking
Revenue grew 15.5% and profit hit targets, but Crop Protection's EBITDA margin collapsed from 15–17% guidance to 11%. Trade receivables jumped to ₹220 Cr and TiO2 operations are now suspended indefinitely. The headline beat obscures real operational stress.
₹666.9 Cr
+15.5% YoY, +22.9% QoQ
₹33.9 Cr
+193% YoY, −29.7% QoQ
11%
Crop Protection guidance 15–17%, delivered 11%
₹220 Cr
DSO extended to 110–115 days
Meghmani Organics delivered on the headline: ₹666.9 Cr revenue and ₹33.9 Cr profit hit consolidated targets exactly. But the quarter masks a deterioration in operational quality. Crop Protection, which is 75% of revenue at ₹496 Cr, has an EBITDA margin of 11% — a 4–6 percentage point miss against the company's own 15–17% guidance. Raw material costs, particularly sulfuric acid, have spiked 7–8 times normal levels. Logistics costs have surged. Trade receivables jumped to ₹220 Cr with payment cycles extended from 100–110 days to 110–115 days, signaling that the company is offering credit to push sales in a softening market. And the TiO2 segment, once a profit contributor, is now suspended indefinitely because restarting is commercially unviable at current raw material costs.
The profit number, while impressive on paper at +193% YoY, sits on a very weak base: Q2 FY26 earned just ₹11.8 Cr. More concerning, Q2 profit fell 29.7% quarter-over-quarter from Q1 FY27, implying that the first quarter was materially stronger on margin. Half-year revenue of ₹1,181 Cr is only +3% YoY — a pace that Q2's +15.5% growth cannot sustain. Q1 must have been near-flat or negative, which raises questions about the strength of underlying demand.
Management's claims versus what holds up
Consolidated revenue ₹666 Cr, up 16% YoY
Delivered ₹666.9 Cr, +15.5% YoY
Supported
Consolidated net profit ₹33.9 Cr, up 193% YoY
Delivered ₹33.9 Cr PAT, +193.3% YoY
Supported (but on small base)
Crop Protection 15–17% EBITDA margin target maintained
Segment delivered 11% EBITDA (₹54 Cr on ₹496 Cr revenue)
Overstated — margin miss of 4–6 pts
Logistics cost rising gradually, normalizing
Management acknowledges 'sharp increase'; normalization timeline vague; DSO extended
Contradicted — costs not normalizing yet
EBITDA grew 40% YoY to ₹73 Cr
Implied EBITDA ~₹73–74 Cr; growth rate aligns
Supported on the growth rate
What changed on this call
This quarter brings three material shifts. First, TiO2 is now suspended indefinitely. The company had been operating a titanium dioxide segment; it was suspended in response to a re-imposed antidumping duty (October 2026) combined with sulfuric acid costs at 7–8 times normal levels, making restart 'not commercially viable' in the foreseeable future. Management has offered no timeline for a restart — it is exploring strategic options but gave no specifics. For a prior profit contributor, this is a structural impairment that the company has not yet written down.
Second, working capital has deteriorated. Trade receivables jumped to ₹220 Cr. Management extended the payment cycle from 100–110 days to 110–115 days to support customers in a 'challenging market.' This is not merely a seasonal working capital swing; it signals either credit risk (customers cannot pay on the old terms) or demand softness (the company must offer credit to move volume). The risk of bad debts rising is real, though not yet quantified.
Third, Crop Nutrition conviction has upgraded. Management reaffirmed very optimistic long-term outlook and claimed that new Nano products (Nano DAP, Nano NPK, Nano Zinc) will contribute 20–22% of consolidated EBITDA over the next 3 years. Prior guidance was ₹100 Cr revenue over 2–3 years, which translates to ~₹33 Cr annually. The new EBITDA target is materially more ambitious. However, execution risk is high: Nano urea (a competing product) has struggled with adoption. Management is confident Nano DAP will fare better, but this is early-stage and unproven at scale.
The bull case and the bear case
Revenue momentum solid at 15.5% YoY
Consolidated numbers (₹666.9 Cr, ₹33.9 Cr) hit exactly
Debt repayment on track; leverage low
Long-term product pipeline to 2031; 70+ countries
Crop Protection margin missed 15–17% guidance by 4–6 pts
Raw material (sulfuric acid) costs 7–8x normal; recovery timeline vague
Trade receivables ₹220 Cr; DSO extended; signals market stress
TiO2 operations suspended indefinitely
QoQ profit fell 29.7%; HY growth only 3% YoY vs Q2's 15.5%
Crop Nutrition very early stage; adoption risk on Nano products
Risks ranked by how much they should concern a holder
Crop Protection margin recovery uncertain
HighGuided 15–17% EBITDA; delivered 11%. Raw materials remain elevated (7–8x normal) with no quantified timeline for normalization. If cost pressure persists into Q3 and Q4, the recovery won't happen this fiscal year. The company's credibility on near-term execution is now in question.
Trade receivables spike and DSO extension
High₹220 Cr receivables with payment cycles at 110–115 days (extended from 100–110) is a red flag. Management attributed this to credit extension in a challenging market. If receivables don't normalize and bad debts rise, working capital will deteriorate further, pressuring cash flow and debt paydown.
TiO2 segment suspended indefinitely
HighA former profit contributor is now a dead asset. Sulfuric acid costs remain uneconomic and there is a 5-year antidumping duty (Oct 2026 onwards). No restart timeline given. The company will likely have to write down or divest the asset, crystallizing a loss. This is unquantified and hanging over the stock.
Half-year revenue growth deceleration
MediumHY revenue ₹1,181 Cr is only +3% YoY, but Q2 was +15.5%. This implies Q1 was near-flat or negative. Sequential weakness suggests Q2's growth is not sustainable. Next quarter, if Q3 slows again, the long-term growth thesis comes into question.
Crop Nutrition execution and adoption risk
MediumManagement is very bullish on Nano products contributing 20–22% of consolidated EBITDA over 3 years. But Nano urea (a competing product) has struggled with adoption. Nano DAP is in early-stage field trials. Execution risk is high; the ramp may take longer than expected or fail entirely, eroding the long-term growth case.
Geopolitical and tariff headwinds
MediumUS tariffs impact pigment exports; Europe is a weak market. Re-imposed antidumping duty on TiO2 has already suspended that segment. Further trade friction could pressurize margins across segments.
How the street sees it
The stock is trading at ₹54.27, down 64% from its all-time high of ₹152.5 but up 49% off its 52-week low of ₹36.5. It sits below its 20-day moving average (₹55.52) and well below its 50-day (₹58.9), though above its 200-day (₹53.43). RSI is 44.5, indicating neutral momentum with a tilt towards oversold. Volume has been normal; no panic liquidation. The post-result price action will clarify whether the market is pricing in the margin miss or overlooking it in favor of long-term growth.
On ownership, FII holdings have declined from 1.34% in FY26 Q4 to 0.91% in FY27 Q1 — a 43 basis point withdrawal over one quarter. DII presence is negligible at 0.00%. Promoter ownership remains stable at ~49%, indicating no insider selling. Recent bulk/block deals (last 6 months) show institutional flow but no red flags: NK Securities and QE Securities bought and sold in the ₹57.70–57.82 range in matched transactions, suggesting neutral positioning. No promoter-linked selling near the all-time high. However, the FII withdrawal during a quarter of announced guidance miss is a signal that foreign institutions are not confident in the near-term recovery narrative.
1 · Q3 FY27 (Dec 2026 results): Input cost and logistics normalization
The next quarter will clarify whether sulfuric acid costs and logistics premiums are normalizing. If Crop Protection EBITDA margin improves even modestly (to 12–13%), the recovery narrative gains credibility. If it stays at 11% or worsens, the company's cost management claims are hollow and the margin guidance reset is necessary.
2 · Trade receivables and DSO trajectory
Watch whether receivables normalize back towards the 100–110 day cycle or remain elevated at 110–115 days. If they stay high or worsen into Q3, it confirms persistent market softness and rising bad-debt risk. If they fall sharply, it confirms the credit extension was temporary and demand is stabilizing.
3 · Crop Nutrition revenue visibility
By H2 FY27 or Q1 FY28, Nano DAP and Nano NPK should show measurable revenue contribution (even if immaterial to consolidated results). Field trials are said to be positive, but until actual sales appear in the income statement, the 20–22% EBITDA contribution target is speculation. Early signs of customer offtake would validate the long-term thesis.
Meghmani Organics is in a transition quarter, not a growth inflection. The headline — revenue up 15.5%, profit up 193% — masks a softer operational reality: margins halved, working capital extended, and a segment suspended. Management's long-term conviction (double-digit growth, 13–14% consolidated EBITDA margin, Crop Nutrition scale) is credible on paper, supported by a product pipeline and debt discipline. But near-term execution has stumbled. The company will earn conviction only if it proves cost normalization and Crop Nutrition revenue materialize by year-end.
The number to track from here is the Crop Protection EBITDA margin in Q3. If it recovers towards 12–13%, the quarter was a blip and the hold case strengthens. If it remains at 11%, management's guidance is not worth the paper it is written on, and downside risk widens.